-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From imitation to innovation, the development of the pharmaceutical industry is a process of continuous exploration and breakthroughs.
Since 2016, driven by various factors such as policies, technology, and capital markets, China’s innovative drug industry has begun to develop rapidly.
The enthusiasm for innovation of pharmaceutical companies is increasing, R&D investment is continuously increasing, and the number of approved new drugs is increasing.
At the same time, in the case of fierce competition in the living environment, some powerful local innovative pharmaceutical companies have also begun to "go global".
.
In the wave of innovative drug companies going out to the sea, BeiGene has been very active.
On December 21, BeiGene announced that the company and Novartis have reached a cooperation agreement, and Novartis will obtain BeiGene's tumor drug TIGIT antibody in the United States, Canada, and Europe.
For multi-country and Japanese interests, Novartis will pay an upfront payment of US$300 million, an additional payment of US$600 million or US$700 million, a milestone of US$1.
895 billion, and a sales share of 20%-25%
.
And on January 12 this year, BeiGene announced that it had cooperated with Novartis on its independent research and development of PD-1 anti-cancer drug Bezean (generic name: tislelizumab injection) in the United States, the United Kingdom, Russia, Japan, etc.
The development, production and commercialization of more than 10 countries have reached cooperation and licensing agreements, with a total transaction value of more than 2.
2 billion US dollars
.
At present, BeiGene has innovated the record of the authorized transaction amount and the down payment amount of a single domestic drug
.
In addition to BeiGene, on August 8 this year, Rongchang Biotech announced that it has reached an exclusive global license agreement with Seattle Gene.
Seattle Gene will develop and commercialize Rongchang Biotech's new ADC drug, Vidicituzumab
.
The total potential revenue of Rongchang Bio will be as high as 2.
6 billion US dollars, including 200 million US dollars down payment and up to 2.
4 billion US dollars in milestone payments
.
In addition, since 2021, many Chinese biopharmaceutical companies such as Jacos, Alis Pharmaceuticals, Junshi Biotech, China Biopharmaceuticals, etc.
have gone overseas to enter the global market through overseas authorization (License-out) and other forms
.
According to incomplete statistics in the industry, as of the end of September, there have been 22 license-out transactions among Chinese pharmaceutical companies, with a transaction volume exceeding 3.
5 billion U.
S.
dollars
.
Compared with directly promoting the listing of drugs overseas, the license-out model is obviously more accepted by pharmaceutical companies
.
According to statistics, from 2017 to 2019, the number of domestically-made innovative drugs sold in the form of license out was less than 10, but starting from 2020, this number has soared to 39
.
Behind the increasing number of license-out projects is the improvement of the innovation capabilities of Chinese local innovative companies and the performance of being more recognized by foreign markets and partners
.
The industry predicts that in the context of the gradual trend of local innovative drugs going overseas, the number of license-out projects will increase in the future
.
It is worth mentioning that local innovative drug companies are also facing some challenges when going overseas
.
For example, overseas clinical practice requires a large amount of R&D funding support, and local pharmaceutical companies’ own technologies are also facing consideration, including the need to have the ability to carry out global clinical trials and the company’s commercialization strategy
.
For example, in order to enrich the supply chain and expand production capacity, BeiGene announced on November 23 that it had completed the acquisition of land for the Princeton West Innovation Park in Hopewell, New Jersey, USA, for the construction of an area of 42 Acre (approximately 170,000 square meters) of innovative medicine production base
.
Regarding the construction of the production base, the company stated that the main purpose is to further expand and enrich the company's global supply chain, and to build new production capacity for the company's deep biopharmaceutical product pipeline and drug candidates
.
In general, although domestically-made innovative drugs have become a trend to go overseas, not all companies have the ability to meet the above challenges.
To promote China's truly independent research and development of innovative drugs to overseas markets still needs to go through a twists and turns
.
Since 2016, driven by various factors such as policies, technology, and capital markets, China’s innovative drug industry has begun to develop rapidly.
The enthusiasm for innovation of pharmaceutical companies is increasing, R&D investment is continuously increasing, and the number of approved new drugs is increasing.
At the same time, in the case of fierce competition in the living environment, some powerful local innovative pharmaceutical companies have also begun to "go global".
.
In the wave of innovative drug companies going out to the sea, BeiGene has been very active.
On December 21, BeiGene announced that the company and Novartis have reached a cooperation agreement, and Novartis will obtain BeiGene's tumor drug TIGIT antibody in the United States, Canada, and Europe.
For multi-country and Japanese interests, Novartis will pay an upfront payment of US$300 million, an additional payment of US$600 million or US$700 million, a milestone of US$1.
895 billion, and a sales share of 20%-25%
.
And on January 12 this year, BeiGene announced that it had cooperated with Novartis on its independent research and development of PD-1 anti-cancer drug Bezean (generic name: tislelizumab injection) in the United States, the United Kingdom, Russia, Japan, etc.
The development, production and commercialization of more than 10 countries have reached cooperation and licensing agreements, with a total transaction value of more than 2.
2 billion US dollars
.
At present, BeiGene has innovated the record of the authorized transaction amount and the down payment amount of a single domestic drug
.
In addition to BeiGene, on August 8 this year, Rongchang Biotech announced that it has reached an exclusive global license agreement with Seattle Gene.
Seattle Gene will develop and commercialize Rongchang Biotech's new ADC drug, Vidicituzumab
.
The total potential revenue of Rongchang Bio will be as high as 2.
6 billion US dollars, including 200 million US dollars down payment and up to 2.
4 billion US dollars in milestone payments
.
In addition, since 2021, many Chinese biopharmaceutical companies such as Jacos, Alis Pharmaceuticals, Junshi Biotech, China Biopharmaceuticals, etc.
have gone overseas to enter the global market through overseas authorization (License-out) and other forms
.
According to incomplete statistics in the industry, as of the end of September, there have been 22 license-out transactions among Chinese pharmaceutical companies, with a transaction volume exceeding 3.
5 billion U.
S.
dollars
.
Compared with directly promoting the listing of drugs overseas, the license-out model is obviously more accepted by pharmaceutical companies
.
According to statistics, from 2017 to 2019, the number of domestically-made innovative drugs sold in the form of license out was less than 10, but starting from 2020, this number has soared to 39
.
Behind the increasing number of license-out projects is the improvement of the innovation capabilities of Chinese local innovative companies and the performance of being more recognized by foreign markets and partners
.
The industry predicts that in the context of the gradual trend of local innovative drugs going overseas, the number of license-out projects will increase in the future
.
It is worth mentioning that local innovative drug companies are also facing some challenges when going overseas
.
For example, overseas clinical practice requires a large amount of R&D funding support, and local pharmaceutical companies’ own technologies are also facing consideration, including the need to have the ability to carry out global clinical trials and the company’s commercialization strategy
.
For example, in order to enrich the supply chain and expand production capacity, BeiGene announced on November 23 that it had completed the acquisition of land for the Princeton West Innovation Park in Hopewell, New Jersey, USA, for the construction of an area of 42 Acre (approximately 170,000 square meters) of innovative medicine production base
.
Regarding the construction of the production base, the company stated that the main purpose is to further expand and enrich the company's global supply chain, and to build new production capacity for the company's deep biopharmaceutical product pipeline and drug candidates
.
In general, although domestically-made innovative drugs have become a trend to go overseas, not all companies have the ability to meet the above challenges.
To promote China's truly independent research and development of innovative drugs to overseas markets still needs to go through a twists and turns
.
